Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3479-3485

  Wong, Hilda ^a   Wong, Kai P ^a   Yau, Thomas ^a   Tang, Vikki ^a   Leung, Roland ^a   Chiu, Joanne ^a   Lang, Brian Hung Hin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ABLATION TECHNIQUES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; ROC CURVE; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS; YOUNG ADULT;

EID: 84868214910     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2391-6     Document Type: Article

References (23)

1. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-11. (Pubitemid 36173719)
2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-28. (Pubitemid 24345593)
3. Zanotti-Fregonara P, Keller I, Calzada-Nocaudie M, et al. Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients: Are there sources of benign secretion? A speculative short review. Nucl Med Commun. 2010;31:1054-8.
4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Thyroid carcinoma. Version 1.2011.http://www.nccn.org.
5. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem. 1996;42:164-73. (Pubitemid 26030404)
6. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121-7. (Pubitemid 28496379)
7. Giovanella L, Keller F, Ceriani L, Tozzoli R. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem LabMed. 2009;47:952-4.
8. Pacini F, Lari R, Mazzeo S, et al. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 1985;23:405-11. (Pubitemid 16216760)
9. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-85. (Pubitemid 30644169)
10. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin- stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90:5047-57. (Pubitemid 41262253)
11. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926-32. (Pubitemid 43357760)
12. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid. 1997;7:273-6. (Pubitemid 27190595)
13. Alzahrani AS, Mohamed G, Al Shammary A, et al. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. J Endocrinol Invest. 2005;28:540-6. (Pubitemid 43162888)
14. Lang BH, Lo CY, Chan WF, et al. Staging systems for papillary thyroid carcinoma: A review and comparison. Ann Surg. 2007; 245:366-78. (Pubitemid 46673133)
15. Shaha AR. TNM classification of thyroid carcinoma. World J Surg. 2007;31:879-87. (Pubitemid 46716781)
16. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114: 1050-7.
17. Castagna MG, Tala Jury HP, Cipri C, et al. The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest. 2011;34:e219-23.
18. Schlumberger M, Hitzel A, Toubert ME, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab. 2007;92:2487-95. (Pubitemid 47037347)
19. Baudin E, Do Cao C, Cailleux AF, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003;88:1107-11. (Pubitemid 36337763)
20. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20: 1341-9.
21. Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21:707-16.
22. van Dijk D, Plukker JT, van der Horst-Schrivers AN, et al. The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial 131I therapy. Clin Endocrinol (Oxf). 2011;74:104-10.
23. Papageorgiou MS, Liratzopoulos N, Minopoulos G, Manolas KJ. Thyroglobulin - what is the postoperative threshold for the suspicion of thyroid cancer recurrence in the absence of anti-Tg antibody measurement? S Afr J Surg. 2011;49:118-22.